Medtech companies need to take heed as Chinese corruption clampdown spreads
This article was originally published in SRA
Medtech companies doing business in China would do well to conduct a special internal audit as Chinese authorities intensify their scrutiny on inappropriate conduct within the healthcare industry.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.